 to its portfolio.){kind=link}
Nasdaq-listed Bionexus Gene Lab has added Ethereum (ETH) to its portfolio, increasing the size of its treasury holdings.
For the biotech company, which is renowned for its emphasis on gene therapy and biotechnology breakthroughs, this move represents a big milestone.
On 5th March 2025, according to the firm’s official announcement, the firm has become the first biotech company to have Ethereum as a part of its treasury.
Bionexus’ Move Comes as More Institutions Keep Digital Assets As a Part of Reserve
Bionexus Gene Lab has joined an increasing number of businesses that understand the potential of digital assets as a store of value and a hedge against conventional financial market fluctuations by diversifying its treasury with Ethereum.
The choice to invest in Ethereum is indicative of how cryptocurrencies are becoming more and more accepted in traditional sectors.
The second-largest cryptocurrency by market capitalization, Ethereum, is regarded as a promising long-term asset because of its strong blockchain architecture and extensive usage in smart contracts and decentralized applications (dApps).
Bionexus hopes to improve its financial flexibility and keep up with developments in the rapidly changing digital economy by owning Ethereum.
Bionexus Explains Reason Behind Choosing Ethereum
Bionexus in its release stated that after conducting a thorough examination, the Board had concluded that Ethereum offers a strategic treasury management solution because of a number of important considerations.
First off, the adoption of Ethereum by significant financial institutions and exchange-traded funds (ETFs) demonstrates its institutional credibility.
Furthermore, the Proof-of-Stake (PoS) mechanism of Ethereum has yield-generation capabilities, enabling staking to generate passive income.
Ethereum supports trillions of dollars in stablecoin transactions per year, demonstrating its dominance in the financial infrastructure.
Additionally, the impending Ethereum upgrades—like the big Pectra upgrade—promise improved scalability and efficiency, setting Ethereum primed for long-term expansion and increased acceptance.
“By integrating Ethereum into our corporate treasury, BioNexus Gene Lab Corp. is embracing the future of financial infrastructure,” said Sam Tan, CEO.
He added, “Ethereum offers high liquidity, utility, and stability compared to other digital assets, positioning BGLC as a leader in blockchain-integrated corporate finance. Wyoming’s regulatory leadership further validates our decision, as it fosters an environment where blockchain businesses can thrive.”
Bionexus To Benefit From Wyoming’s Progressive Blockchain Legislation
With the new inclusion to its treasury, Bionexus aims at benefitting from Wyoming’s progressive blockchain legislation. Wyoming’s pro-business regulatory climate encourages blockchain innovation, and BGLC, one of the few publicly traded firms formed in the state, benefits from this.
With its comprehensive legislative frameworks for corporate governance, financial innovation, and the custody of digital assets, Wyoming has established itself as a leader in blockchain legislation.